127 related articles for article (PubMed ID: 32228125)
1. Insights into structures of imidazo oxazines as potent polyketide synthase XIII inhibitors using molecular modeling techniques.
B S; M K K
J Recept Signal Transduct Res; 2020 Aug; 40(4):313-323. PubMed ID: 32228125
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new oxadiazolo pyridine derivatives as potent ghrelin O-acyltransferase inhibitors using molecular modeling techniques.
Sarkar K; Das B; Das RK
In Silico Pharmacol; 2023; 11(1):35. PubMed ID: 37954893
[TBL] [Abstract][Full Text] [Related]
3. Targeting polyketide synthase 13 for the treatment of tuberculosis.
Xia F; Zhang H; Yang H; Zheng M; Min W; Sun C; Yuan K; Yang P
Eur J Med Chem; 2023 Nov; 259():115702. PubMed ID: 37544185
[TBL] [Abstract][Full Text] [Related]
4. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel inhibitors for mycobacterial polyketide synthase 13 via in silico drug screening assisted by the parallel compound screening with genetic algorithm-based programs.
Taira J; Murakami K; Monobe K; Kuriki K; Fujita M; Ochi Y; Sakamoto H; Aoki S
J Antibiot (Tokyo); 2022 Oct; 75(10):552-558. PubMed ID: 35941150
[TBL] [Abstract][Full Text] [Related]
6. 3D-QSAR Selectivity Analysis of 1-Adamantyl-3-Heteroaryl Urea Analogs as Potent Inhibitors of Mycobacterium tuberculosis.
Wadhwa P; Bagchi S; Sharma A
Curr Comput Aided Drug Des; 2015; 11(2):164-83. PubMed ID: 26234390
[TBL] [Abstract][Full Text] [Related]
7. Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis. Part II.
Zhang W; Lun S; Liu LL; Xiao S; Duan G; Gunosewoyo H; Yang F; Tang J; Bishai WR; Yu LF
J Med Chem; 2019 Apr; 62(7):3575-3589. PubMed ID: 30875203
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Optimization of Coumestan Derivatives as Polyketide Synthase 13-Thioesterase(Pks13-TE) Inhibitors with Improved hERG Profiles for
Zhang W; Lun S; Wang SS; Cai YP; Yang F; Tang J; Bishai WR; Yu LF
J Med Chem; 2022 Oct; 65(19):13240-13252. PubMed ID: 36174223
[TBL] [Abstract][Full Text] [Related]
9. Virtual generation of agents against Mycobacterium tuberculosis. A QSAR study.
Besalú E; Ponec R; de Julián-Ortiz JV
Mol Divers; 2003; 6(2):107-20. PubMed ID: 14761161
[TBL] [Abstract][Full Text] [Related]
10. Molecular insights into benzene sulphonamide substituted diarylpyrazoles as cyclooxygenase-2 inhibitor and its structural modifications.
Priya D; Kathiravan MK
J Biomol Struct Dyn; 2021 Sep; 39(14):5093-5104. PubMed ID: 32602808
[TBL] [Abstract][Full Text] [Related]
11. Lignans and Neolignans Anti-tuberculosis Identified by QSAR and Molecular Modeling.
S Maia M; de Sousa NF; Rodrigues GCS; Monteiro AFM; Scotti MT; Scotti L
Comb Chem High Throughput Screen; 2020; 23(6):504-516. PubMed ID: 32101116
[TBL] [Abstract][Full Text] [Related]
12. Similarity approach to QSAR. Application to antimycobacterial benzoxazines.
Gallegos A; Carbó-Dorca R; Ponec R; Waisser K
Int J Pharm; 2004 Jan; 269(1):51-60. PubMed ID: 14698576
[TBL] [Abstract][Full Text] [Related]
13. Development of a Novel Lead that Targets M. tuberculosis Polyketide Synthase 13.
Aggarwal A; Parai MK; Shetty N; Wallis D; Woolhiser L; Hastings C; Dutta NK; Galaviz S; Dhakal RC; Shrestha R; Wakabayashi S; Walpole C; Matthews D; Floyd D; Scullion P; Riley J; Epemolu O; Norval S; Snavely T; Robertson GT; Rubin EJ; Ioerger TR; Sirgel FA; van der Merwe R; van Helden PD; Keller P; Böttger EC; Karakousis PC; Lenaerts AJ; Sacchettini JC
Cell; 2017 Jul; 170(2):249-259.e25. PubMed ID: 28669536
[TBL] [Abstract][Full Text] [Related]
14. Molecular dynamics simulation and binding free energy studies of novel leads belonging to the benzofuran class inhibitors of Mycobacterium tuberculosis Polyketide Synthase 13.
Cruz JN; Costa JFS; Khayat AS; Kuca K; Barros CAL; Neto AMJC
J Biomol Struct Dyn; 2019 Apr; 37(6):1616-1627. PubMed ID: 29633908
[TBL] [Abstract][Full Text] [Related]
15. In silico discovery and virtual screening of multi-target inhibitors for proteins in Mycobacterium tuberculosis.
Speck-Planche A; Kleandrova VV; Luan F; Cordeiro MN
Comb Chem High Throughput Screen; 2012 Sep; 15(8):666-73. PubMed ID: 22452349
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds.
Ventura C; Latino DA; Martins F
Eur J Med Chem; 2013; 70():831-45. PubMed ID: 24246731
[TBL] [Abstract][Full Text] [Related]
17. Structure-Based Design and in Silico Screening of Virtual Combinatorial Library of Benzamides Inhibiting 2-trans Enoyl-Acyl Carrier Protein Reductase of
Kouman KC; Keita M; Kre N'Guessan R; Owono Owono LC; Megnassan E; Frecer V; Miertus S
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31554227
[TBL] [Abstract][Full Text] [Related]
18. A QSAR study of biphenyl analogues of 2-nitroimidazo-[2, 1-b] [1, 3]-oxazines as antitubercular agents using genetic function approximation.
Ray S; Roy PP
Med Chem; 2012 Jul; 8(4):717-26. PubMed ID: 22530914
[TBL] [Abstract][Full Text] [Related]
19. Design of novel quinoline-aminopiperidine derivatives as
Wang J; Zhao C; Tu J; Yang H; Zhang X; Lv W; Zhai H
J Biomol Struct Dyn; 2019 Jul; 37(11):2913-2925. PubMed ID: 30044186
[TBL] [Abstract][Full Text] [Related]
20. Molecular docking-based interactions in QSAR studies on
Ahmed S; Prabahar AE; Saxena AK
SAR QSAR Environ Res; 2022 Apr; 33(4):289-305. PubMed ID: 35532308
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
